Awaji, A.A.; Rizk, M.A.; Alsaiari, R.A.; Alqahtani, N.F.; Al-Qadri, F.A.; Alkorbi, A.S.; Hafez, H.S.; Elshaarawy, R.F.M.
Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. Pharmaceuticals 2025, 18, 1287.
https://doi.org/10.3390/ph18091287
AMA Style
Awaji AA, Rizk MA, Alsaiari RA, Alqahtani NF, Al-Qadri FA, Alkorbi AS, Hafez HS, Elshaarawy RFM.
Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. Pharmaceuticals. 2025; 18(9):1287.
https://doi.org/10.3390/ph18091287
Chicago/Turabian Style
Awaji, Aeshah A., Moustafa A. Rizk, Raiedhah A. Alsaiari, Norah F. Alqahtani, Fatima A. Al-Qadri, Ali S. Alkorbi, Hani S. Hafez, and Reda F. M. Elshaarawy.
2025. "Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711" Pharmaceuticals 18, no. 9: 1287.
https://doi.org/10.3390/ph18091287
APA Style
Awaji, A. A., Rizk, M. A., Alsaiari, R. A., Alqahtani, N. F., Al-Qadri, F. A., Alkorbi, A. S., Hafez, H. S., & Elshaarawy, R. F. M.
(2025). Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. Pharmaceuticals, 18(9), 1287.
https://doi.org/10.3390/ph18091287
